
Humana (HUM) Stock Forecast & Price Target
Humana (HUM) Analyst Ratings
Bulls say
Humana is well positioned because 3Q26 showed a 30c EPS beat, a 93.7% Insurance benefit ratio versus 94.3% expected, and management raised 2026 adjusted EPS guidance to at least $9.50 as medical cost trends held at the low end of the prior 7-8% range. The company’s core Medicare Advantage franchise is improving on stronger enrollment, retention, and pricing discipline, while individual MA margins are expected to materially expand in 2027 and reach about 3.2% in 2028, supported by improved Stars scores. Meanwhile, CenterWell membership is up about 30%, the balance sheet is strengthening with debt-to-cap falling to 40.9%, and the new JV structure adds capital flexibility and optionality.
Bears say
Humana is facing a deteriorating Medicare Advantage margin recovery story, with normalized margins potentially pushed beyond 2028 and low visibility into near-term medical-loss-ratio improvement as deferred care trends remain uncertain. Competitive pressure is intensifying as legacy and emerging insurers target MA growth, while legislative and reimbursement risks around benchmark cuts, coding intensity adjustments, and home visit coding could further compress rates. The outlook is also weakened by a roughly (3.0%) Group MA Stars headwind in CY26 and estimated Group MA margins of only ~(4.0%) in CY26, even before Medicaid redetermination and exchange-subsidy pressures.
This aggregate rating is based on analysts' research of Humana and is not a guaranteed prediction by Public.com or investment advice.
Humana (HUM) Analyst Forecast & Price Prediction
Start investing in Humana (HUM)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Humana (HUM) Forecast
Humana (HUM) Analyst Forecast & Price Prediction
Start investing in Humana (HUM)
Order type
Buy in
Order amount
Est. shares
0 shares